Braco-19

Modify Date: 2024-01-02 17:58:27

Braco-19 Structure
Braco-19 structure
Common Name Braco-19
CAS Number 351351-75-2 Molecular Weight 593.76200
Density 1.275g/cm3 Boiling Point 854.95ºC at 760 mmHg
Molecular Formula C35H43N7O2 Melting Point N/A
MSDS N/A Flash Point 470.857ºC

 Use of Braco-19


Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor[1][2].

 Names

Name N-[9-[4-(dimethylamino)anilino]-6-(3-pyrrolidin-1-ylpropanoylamino)acridin-3-yl]-3-pyrrolidin-1-ylpropanamide
Synonym More Synonyms

 Braco-19 Biological Activity

Description Braco-19 is a potent telomerase/telomere inhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virus replication inhibitor[1][2].
Related Catalog
Target

IC50: telomerase/telomere[1]

In Vitro Braco-19, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication[2]. BRACO-19 (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC50 for BRACO-19 in UXF1138L cells is 2.5 μM, the IC100 is 5 μM[1]. BRACO-19 (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses[1]. BRACO-19 (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells[2]. BRACO-19 (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner[2]. Cell Viability Assay[1] Cell Line: HEK 293 cells Concentration: 20 μM; 40 μM Incubation Time: 24 hours Result: Displayed low cytotoxicity and decreased the eGFP fluorescence.
In Vivo BRACO-19 (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts[1]. BRACO-19 (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors)[1]. Animal Model: Established UXF1138LX Xenografts in nude mice[1] Dosage: 2 mg/kg Administration: Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments Result: Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control.
References

[1]. Angelika M Burger, et al. The G-quadruplex-interactive Molecule BRACO-19 Inhibits Tumor Growth, Consistent With Telomere Targeting and Interference With Telomerase Function. Cancer Res. 2005 Feb 15;65(4):1489-96.

[2]. Prativa Majee, et al. Genome-wide Analysis Reveals a Regulatory Role for G-quadruplexes During Adenovirus Multiplication. Virus Res. . 2020 Jul

 Chemical & Physical Properties

Density 1.275g/cm3
Boiling Point 854.95ºC at 760 mmHg
Molecular Formula C35H43N7O2
Molecular Weight 593.76200
Flash Point 470.857ºC
Exact Mass 593.34800
PSA 103.05000
LogP 6.64310
Index of Refraction 1.708

 Safety Information

Hazard Codes Xi

 Synthetic Route

~85%

Braco-19 Structure

Braco-19

CAS#:351351-75-2

Literature: Neidle, Stephen; Harrison, Richard John; Kelland, Llyod Royston; Gowan, Sharon Michele; Read, Martin Anthony; Reszka, Anthony Patent: US2003/207909 A1, 2003 ; Location in patent: Page/Page column 48 ; US 20030207909 A1

~%

Braco-19 Structure

Braco-19

CAS#:351351-75-2

Literature: Harrison, R. John; Cuesta, Javier; Chessari, Gianni; Read, Martin A.; Basra, Sanji K.; Reszka, Anthony P.; Morrell, James; Gowan, Sharon M.; Incles, Christopher M.; Tanious, Farial A.; Wilson, W. David; Kelland, Lloyd R.; Neidle, Stephen Journal of Medicinal Chemistry, 2003 , vol. 46, # 21 p. 4463 - 4476

~%

Braco-19 Structure

Braco-19

CAS#:351351-75-2

Literature: Martins, Cristina; Gunaratnam, Mekala; Stuart, John; Makwana, Vaidahi; Greciano, Olga; Reszka, Anthony P.; Kelland, Lloyd R.; Neidle, Stephen Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 8 p. 2293 - 2298

~%

Braco-19 Structure

Braco-19

CAS#:351351-75-2

Literature: Martins, Cristina; Gunaratnam, Mekala; Stuart, John; Makwana, Vaidahi; Greciano, Olga; Reszka, Anthony P.; Kelland, Lloyd R.; Neidle, Stephen Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 8 p. 2293 - 2298

~%

Braco-19 Structure

Braco-19

CAS#:351351-75-2

Literature: Martins, Cristina; Gunaratnam, Mekala; Stuart, John; Makwana, Vaidahi; Greciano, Olga; Reszka, Anthony P.; Kelland, Lloyd R.; Neidle, Stephen Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 8 p. 2293 - 2298

~%

Braco-19 Structure

Braco-19

CAS#:351351-75-2

Literature: Martins, Cristina; Gunaratnam, Mekala; Stuart, John; Makwana, Vaidahi; Greciano, Olga; Reszka, Anthony P.; Kelland, Lloyd R.; Neidle, Stephen Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 8 p. 2293 - 2298

~%

Braco-19 Structure

Braco-19

CAS#:351351-75-2

Literature: Martins, Cristina; Gunaratnam, Mekala; Stuart, John; Makwana, Vaidahi; Greciano, Olga; Reszka, Anthony P.; Kelland, Lloyd R.; Neidle, Stephen Bioorganic and Medicinal Chemistry Letters, 2007 , vol. 17, # 8 p. 2293 - 2298

 Synonyms

N-{9-[4'-(N,N-dimethylamino)phenylamino]}-3,6-bis(3-pyrrolidinopropionamido)acridine
UNII-Z7C5CD91WI
N,N'-(9-((4-(Dimethylamino)phenyl)amino)-3,6-acridinediyl)bis(1-pyrrolidinepropanamide)
BRACO-19
9-[4-(N,N-dimethylamino)phenylamino]-3,6-bis(3-pyrrolodinopropionamido) acridine
1-Pyrrolidinepropanamide,N,N'-(9-((4-(dimethylamino)phenyl)amino)-3,6-acridinediyl)bis
Top Suppliers:I want be here



Get all suppliers and price by the below link:

Braco-19 suppliers

Braco-19 price